This topic has been rescheduled into the work programme as a Single Technology Appraisal within the Technology Appraisal (TA) process, following feedback from the company and stakeholders that eculizumab – which has been available via NHS England’s commissioning statement – should be included as a comparator for this assessment. The company and stakeholders requested NICE reconsider its decision on the comparator as they believe best supportive care (BSC) alone is not the appropriate comparator for this assessment. If NICE acknowledged eculizumab as the comparator for ravulizumab, the only viable approach would be to consider ravulizumab through the TA programme. As such the referral for ravulizumab has been revised from a Highly Specialised Technology (HST) to a TA.